HRP20070452T3 - Sulfonamide derivatives for the treatment of diseases - Google Patents

Sulfonamide derivatives for the treatment of diseases

Info

Publication number
HRP20070452T3
HRP20070452T3 HR20070452T HRP20070452T HRP20070452T3 HR P20070452 T3 HRP20070452 T3 HR P20070452T3 HR 20070452 T HR20070452 T HR 20070452T HR P20070452 T HRP20070452 T HR P20070452T HR P20070452 T3 HRP20070452 T3 HR P20070452T3
Authority
HR
Croatia
Prior art keywords
alkyl
group
cycloalkyl
diseases
treatment
Prior art date
Application number
HR20070452T
Other languages
English (en)
Croatian (hr)
Inventor
D Brown Alan
James Kim
A.L. Lane Charlotte
B. Moses Ian
M. Thomson Nicholas
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20070452(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406388A external-priority patent/GB0406388D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20070452T3 publication Critical patent/HRP20070452T3/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40Y being a hydrogen or a carbon atom
    • C07C323/42Y being a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HR20070452T 2004-01-22 2007-09-27 Sulfonamide derivatives for the treatment of diseases HRP20070452T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04290168 2004-01-22
GB0406388A GB0406388D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
US60025904P 2004-08-09 2004-08-09
PCT/IB2005/000112 WO2005080324A1 (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases

Publications (1)

Publication Number Publication Date
HRP20070452T3 true HRP20070452T3 (en) 2008-02-29

Family

ID=43063961

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070452T HRP20070452T3 (en) 2004-01-22 2007-09-27 Sulfonamide derivatives for the treatment of diseases

Country Status (41)

Country Link
US (1) US7351742B2 (pl)
EP (1) EP1708992B1 (pl)
JP (1) JP4036343B2 (pl)
KR (1) KR100785580B1 (pl)
CN (1) CN1910144B (pl)
AP (1) AP2378A (pl)
AR (1) AR047510A1 (pl)
AT (1) ATE369333T1 (pl)
AU (1) AU2005214154B2 (pl)
BR (1) BRPI0507041A (pl)
CA (1) CA2553293C (pl)
CO (1) CO5720993A2 (pl)
CY (1) CY1106894T1 (pl)
DE (1) DE602005001929T2 (pl)
DK (1) DK1708992T3 (pl)
DO (1) DOP2005000004A (pl)
EA (1) EA009735B1 (pl)
EC (1) ECSP066701A (pl)
ES (1) ES2289691T3 (pl)
GE (1) GEP20084452B (pl)
HK (1) HK1096083A1 (pl)
HN (1) HN2005000030A (pl)
HR (1) HRP20070452T3 (pl)
IL (1) IL176629A (pl)
MA (1) MA28303A1 (pl)
ME (1) ME00557A (pl)
MY (1) MY139690A (pl)
NL (1) NL1028086C2 (pl)
NO (1) NO20063761L (pl)
NZ (1) NZ548235A (pl)
OA (1) OA13361A (pl)
PA (1) PA8621901A1 (pl)
PE (1) PE20050765A1 (pl)
PL (1) PL1708992T3 (pl)
PT (1) PT1708992E (pl)
RS (1) RS50538B (pl)
SI (1) SI1708992T1 (pl)
TW (1) TWI273099B (pl)
UA (1) UA82283C2 (pl)
UY (1) UY28724A1 (pl)
WO (1) WO2005080324A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1907356A2 (en) * 2005-07-18 2008-04-09 Pfizer Limited Process for the preparation of sulfonamide derivatives
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
CA2618089A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR101064787B1 (ko) 2006-03-20 2011-09-14 화이자 리미티드 아민 유도체
DK2013211T3 (da) 2006-04-21 2012-07-02 Novartis Ag Purinderivater til anvendelse som adenosin-A2A-receptoragonister
AU2007303909A1 (en) * 2006-10-04 2008-04-10 Pfizer Limited Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
DE102007018151A1 (de) 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US7713463B1 (en) * 2007-11-13 2010-05-11 Nuvasive, Inc. Method of manufacturing embroidered surgical implants
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
US8263623B2 (en) * 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
AU2009334597B2 (en) 2008-12-30 2015-07-16 Pulmagen Therapeutics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
RU2676686C2 (ru) 2009-04-23 2019-01-10 Тереванс Рэспирэйтори Кампани Эл Эл Си ДИАМИДНЫЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ АНТАГОНИСТА МУСКАРИНОВОГО РЕЦЕПТОРА И АКТИВНОСТЬЮ АГОНИСТА β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
EP2435462A1 (en) 2009-05-29 2012-04-04 Pfizer Limited Novel glucocorticoid receptor agonists
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドPfizer Limited 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
JP6080051B2 (ja) 2011-06-10 2017-02-15 キエスィ ファルマチェウティチ エス.ピー.エー. ムスカリン受容体拮抗薬及びβ2アドレナリン受容体作動薬活性を有する化合物
EA030552B1 (ru) 2012-12-06 2018-08-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
TW201427977A (zh) 2012-12-06 2014-07-16 Chiesi Farma Spa 具有蕈毒鹼受體拮抗劑及β2腎上腺素受體致效劑活性之化合物
AU2021296221A1 (en) 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404224A (en) 1981-12-02 1983-09-13 American Cyanamid Company Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) * 1984-01-31 1985-09-10 Bristol-Myers Company Topical nonsteroidal anti-inflammatory compositions and uses
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
JPH10218861A (ja) 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US7048994B2 (en) * 2001-02-23 2006-05-23 Teijin Limited Laminated polyester film and magnetic recording medium
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
EP1507754A1 (en) * 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists

Also Published As

Publication number Publication date
PE20050765A1 (es) 2005-10-31
EA200601141A1 (ru) 2007-02-27
DOP2005000004A (es) 2005-07-31
AU2005214154A1 (en) 2005-09-01
US7351742B2 (en) 2008-04-01
GEP20084452B (en) 2008-08-10
KR100785580B1 (ko) 2007-12-13
AU2005214154B2 (en) 2008-01-24
UY28724A1 (es) 2005-08-31
AP2006003671A0 (en) 2006-06-30
PL1708992T3 (pl) 2007-12-31
CN1910144A (zh) 2007-02-07
IL176629A (en) 2011-04-28
ES2289691T3 (es) 2008-02-01
DE602005001929T2 (de) 2007-12-06
ME00557A (en) 2011-12-20
DK1708992T3 (da) 2007-11-05
NL1028086A1 (nl) 2005-07-25
NL1028086C2 (nl) 2006-05-09
MY139690A (en) 2009-10-30
US20050171147A1 (en) 2005-08-04
AP2378A (en) 2012-03-08
SI1708992T1 (sl) 2007-12-31
ATE369333T1 (de) 2007-08-15
DE602005001929D1 (de) 2007-09-20
BRPI0507041A (pt) 2007-06-12
AR047510A1 (es) 2006-01-25
NZ548235A (en) 2010-05-28
CA2553293A1 (en) 2005-09-01
HN2005000030A (es) 2009-04-20
PT1708992E (pt) 2007-11-16
NO20063761L (no) 2006-10-23
UA82283C2 (uk) 2008-03-25
CA2553293C (en) 2010-12-14
HK1096083A1 (en) 2007-05-25
WO2005080324A1 (en) 2005-09-01
JP4036343B2 (ja) 2008-01-23
WO2005080324A8 (en) 2006-02-23
PA8621901A1 (es) 2006-03-24
CY1106894T1 (el) 2012-09-26
RS50538B (sr) 2010-05-07
EP1708992B1 (en) 2007-08-08
TWI273099B (en) 2007-02-11
MA28303A1 (fr) 2006-11-01
OA13361A (en) 2007-04-13
IL176629A0 (en) 2006-10-31
TW200530164A (en) 2005-09-16
EA009735B1 (ru) 2008-02-28
CO5720993A2 (es) 2007-01-31
CN1910144B (zh) 2010-06-09
JP2007518790A (ja) 2007-07-12
EP1708992A1 (en) 2006-10-11
ECSP066701A (es) 2006-10-31
KR20060127073A (ko) 2006-12-11

Similar Documents

Publication Publication Date Title
HRP20070452T3 (en) Sulfonamide derivatives for the treatment of diseases
RS50561B (sr) Derivati sulfonamida za lečenje bolesti
AR048322A1 (es) Compuestos para el tratamiento de afecciones inflamatorias, alergicas y respiratorias
MXPA05011666A (es) Compuestos de pirazol-amida aril-sustituidos utiles como inhibidores de cinasa.
AR044475A1 (es) Derivados de 2-amino -piridina utiles para el tratamiento de enfermedades
CO5670367A2 (es) Derivados de acido fenoxiacetico
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
KR960010000A (ko) 종양괴사인자(tnf)생성 저해제로서의 카테콜 디에테르 화합물
HUP0302221A2 (hu) 4-Amino-kinazolinok, eljárás előállításukra, alkalmazásuk és azokat tartalmazó gyógyszerkészítmények
MXPA03011244A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6.
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
RS51888B (en) N- (PHENYL (PIPERIDIN-2-IL) METHYL) BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY
ECSP088479A (es) Derivados de oxadiazol
AR056519A1 (es) 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
CO5611152A2 (es) Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen
DK1633340T3 (da) Forbindelser til behandling af stofskifteforstyrrelser
CO5690608A2 (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica
CL2009001146A1 (es) Compuestos derivados de 5-(5-(2-(3,5-bis(trifluorometil)fenil)-n,2-dimetilpropanoamida)-4-(4-fluoro-2-metilfenil)piridin-2-il)pirrolidin-2-carboxamida, antagonistas de los receptores nk-1; composicion farmaceutica; y uso del compuesto para el tratamiento de la depresion; ansiedad, trastornos del sueño o emesis.
WO2000032578A8 (en) Benzimidazole compounds that are vitronectin receptor antagonists
RS50772B (sr) Pentafluorsulfanil-benzoilgvandini, postupak za njihovu proizvodnju, njihova primena u svojstvu leka ili dijagnostičkog sredstva kao i lek koji sadrži ova jedinjenja
ATE550332T1 (de) 4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors
TW200633710A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
ECSP077394A (es) Compuestos aromáticos de arilsulfonilmetil o arilsulfonamida sustituida apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
BR0208823A (pt) Composto, método de tratamento de distúrbios que são remediados ou aliviados pela atividade de agonista de vasopressina em um mamìfero necessitando do mesmo, e, composição farmacêutica